Literature DB >> 35235382

Reply to J.-G. Wang et al.

Patrick J Leavey1, Mark D Krailo1, Steven G DuBois1, Damon R Reed1, Katherine A Janeway1, Leo Mascarenhas1.   

Abstract

Entities:  

Year:  2022        PMID： 35235382      PMCID： PMC9061146          DOI： 10.1200/JCO.21.02922

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  6 in total

1.  Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.

Authors:  Douglas S Hawkins; Scott Bradfield; James A Whitlock; Mark Krailo; Janet Franklin; Susan M Blaney; Peter C Adamson; Gregory Reaman
Journal:  Pediatr Blood Cancer       Date:  2006-11       Impact factor: 3.167

2.  Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

Authors:  Andrea Hunold; Nicole Weddeling; Michael Paulussen; Andreas Ranft; Caren Liebscher; Herbert Jürgens
Journal:  Pediatr Blood Cancer       Date:  2006-11       Impact factor: 3.167

3.  Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.

Authors:  J Thompson; E O George; C A Poquette; P J Cheshire; L B Richmond; S S de Graaf; M Ma; C F Stewart; P J Houghton
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

4.  Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.

Authors:  R L Saylors; K C Stine; J Sullivan; J L Kepner; D A Wall; M L Bernstein; M B Harris; R Hayashi; T J Vietti
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

5.  Regarding the Children's Oncology Group AEWS1031 Trial for Ewing Sarcoma.

Authors:  Ji-Gan Wang; Qiu-Fen Wei; Qu-Mei Tang
Journal:  J Clin Oncol       Date:  2022-03-02       Impact factor: 50.717

6.  Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report.

Authors:  Patrick J Leavey; Nadia N Laack; Mark D Krailo; Allen Buxton; R Lor Randall; Steven G DuBois; Damon R Reed; Holcombe E Grier; Douglas S Hawkins; Bruce Pawel; Helen Nadel; Richard B Womer; G Douglas Letson; Mark Bernstein; Kenneth Brown; Alexis Maciej; Paul Chuba; Atif A Ahmed; Daniel J Indelicato; Dian Wang; Neyssa Marina; Richard Gorlick; Katherine A Janeway; Leo Mascarenhas
Journal:  J Clin Oncol       Date:  2021-10-15       Impact factor: 50.717
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.